RA Disease Activity Score Most Influential in Patient Reports

Share this content:
RA Disease Activity Score Most Influential in Patient Reports
RA Disease Activity Score Most Influential in Patient Reports

THURSDAY, Nov. 10, 2016 (HealthDay News) -- Higher disease activity score (DAS) is one of the most influential factors for poor patient-reported outcomes (PROs) in rheumatoid arthritis (RA), according to a study published online Nov. 5 in the International Journal of Rheumatic Diseases.

Sang-Cheol Bae, M.D., Ph.D., from the Hanyang University Hospital for Rheumatic Diseases in Seoul, South Korea, and colleagues enrolled 2,000 RA patients aged >20 years and treated with disease-modifying antirheumatic drugs for at least six months. The authors measured health-related quality of life (HRQoL) using the EuroQoL 5D (EQ-5D) and functional disability using the Korean Health Assessment Questionnaire (KHAQ). The correlation between patient characteristics and patient-reported outcomes (PROs) was assessed.

The researchers found that the mean EQ-5D index score was 0.6 ± 0.28 and the mean KHAQ score was 0.7 ± 0.67. Average HRQoL and functional disability scores seemed to be worse in patients with older versus younger age, and in females versus males, in multivariate analysis (both P < 0.001). Patients with moderate and highest DAS had worse outcome measures than patients with lower DAS (P < 0.001).

"In this study, higher DAS was one of the most influential factors for poor PROs among all other factors," the authors write. "Therefore, we could suggest appropriate treatment approaches according to DAS along with other significantly associated factors with PROs in the early stage of RA."

Two authors are employed by Pfizer, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths